Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Illumina Teams Up with Janssen R&D to Propel Development of MRD Liquid Biopsy Test for Oncology Research

NextEdge Admin

08 Dec 2023

1 min 33 sec

MRD Liquid Biopsy Test,Oncology Research

Illumina announced a collaboration agreement with Janssen Research & Development to advance the development of Illumina’s molecular residual disease (MRD) liquid biopsy test for research purposes.

This marks Illumina’s inaugural collaboration for its MRD assay, a comprehensive whole-genome sequencing multi-cancer test designed to identify circulating tumor DNA. Currently in the developmental stage for research applications, Illumina aims to optimize the assay for cost-effectiveness, sensitivity, and automation, targeting a turnaround time of five to seven days.

Joydeep Goswami, Illumina’s CFO and chief strategy and corporate development officer, emphasized the significance of the collaboration, highlighting the value of their unique MRD technology and the potential of Illumina’s whole-genome approach in the field of oncology.

The collaboration with Janssen is part of a broader, long-term strategic partnership initiated in 2022, focused on the development of precision medicines. Illumina also expressed its intention to forge similar collaborations with other pharmaceutical companies for the advancement of its MRD assay.